Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study
2013
Abstract
In a real-life clinical setting, the percentage of patients reaching the combined endpoint of decreasing HbA1c>3 mmol/mol, without hypoglycaemia, peripheral oedema or treatment terminetion due to gastrointestinal side effects was higher after the addition of vildagliptin as compared to other antidiabetic agents with comparable rate of side effects.